Back

Spanish cohort profile, antithrombotic therapy and clinical outcomes at 1 year in the EORP atrial fibrillation long-term registry

28 August 2020 (08:00 - 18:00)
Organised by:
Congress Presentation Part of: Atrial Fibrillation ePosters Clinical ESC Premium Access ESC Congress 2020

About the speaker

Photo
Doctor Jose Miguel Rivera-Caravaca

University of Murcia, Murcia (Spain)

172 More presentations in this session

Presentation thumbnail
Atrial fibrillation with or without structural abnormalities. Analysis from a nationwide database.
Doctor V. Mertz (FR)
Abstract Slides
Presentation thumbnail
Epicardial adipose tissue and atrial fibrillation: guilty as charged or guilty by association?
Doctor J. Sousa (Funchal, PT)
Abstract Slides
Presentation thumbnail
Timing and degree of left atrial stunning and reverse functional remodeling following electrical cardioversion in patients with recent onset atrial fibrillation
Doctor P. Arvanitis (Uppsala, SE)
Abstract Slides
Presentation thumbnail
Irregular beat-to-beat hemodynamic properties determine left ventricular function during atrial fibrillation
Doctor A. Lyon (Maastricht, NL)
Abstract Slides
Presentation thumbnail
Genetic susceptibility, elevated blood pressure and risk of atrial fibrillation
Mr M. Nazarzadeh (Oxford, GB)
Abstract Slides

Access the full session

Session thumbnail
Atrial Fibrillation ePosters

The Event

Event poster

ESC Congress 2020

28 August 2020 08:00 CET
You may be interested in
thumbnail
Congress Presentation
Association between thromboembolic and bleeding risk with adverse outcomes in contemporary European atrial fibrillation patients: final analysis from the ESC-EHRA EORP AF general long-term registry
23 April 2021
thumbnail
Congress Presentation
Oral anticoagulants in older patients with atrial fibrillation: insights from a nationwide study
4 April 2022
thumbnail
Congress Presentation
The first Brazilian cardiovascular registry of atrial fibrillation: The primary results of the RECALL study
27 August 2022
thumbnail
Congress Presentation
Reduction of major adverse and major cardiovascular events in patients with atrial fibrillation and stent implantation treated with left atrial occlusion device vs oral anticoagulants strategy.
26 August 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources